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Commentary
Exposure to 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) is associated with increased
risk for cancer, diabetes, and reproductive
toxicities in numerous epidemiologic studies
(Schecter and Gasiewicz 2003). Several of
these studies base exposure estimates on meas-
urements of blood levels years after accidental
or occupational exposures. Peak exposures
have been estimated in these studies assuming
a mono- or biphasic elimination rate for
TCDD, with estimates of half-life ranging
from 5 to 12 years (Hooiveld et al. 1998;
Michalek et al. 2002; Steenland et al. 2001).
Recent clinical studies suggest that the elimi-
nation rate of TCDD is dose dependent
(Michalek et al. 2002). In experimental ani-
mals, several studies also demonstrate dose-
dependent elimination (Abraham et al. 1988;
Diliberto et al. 2001). In both the animal and
human data, as the exposure dose increases
the apparent half-life decreases, indicating an
inducible elimination of TCDD.
We developed a physiologically based
pharmacokinetic (PBPK) model that describes
the pharmacokinetics of TCDD in rodents
(Emond et al. 2004). This approach is a math-
ematical description of the physiologic, bio-
chemical, and physicochemical processes
involved in the pharmacokinetics of TCDD.
This model, originally validated in rodents,
includes a mathematical description of the
aryl hydrocarbon receptor–mediated induc-
tion of cytochrome P450 1A2 (CYP1A2). In
the model, the elimination rate of TCDD is
dose dependent and is a function of CYP1A2
induction. Experimental evidence suggests that
CYP1A2 is responsible for hepatic seques-
tration of TCDD (Diliberto et al. 1997) and
is also one of the enzymes responsible for its
metabolism (Hakk and Diliberto 2002).
Thus, at low exposures, there is minimal
induction and the elimination of TCDD is
very slow. However, at higher exposures,
induction approaches a maximum and the
elimination rate is much faster. Human phys-
iologic and biochemical parameters were
incorporated into the rodent PBPK model for
species extrapolation.
Materials and Methods
In the present study a rodent PBPK model
(Emond et al. 2004) was extrapolated to
humans. Initial optimization of the human
PBPK model used two data sets. The ﬁrst data
set comes from studies of U.S. Air Force veter-
ans from Operation Ranch Hand. Veterans
involved in Operation Ranch Hand were
responsible for the aerial spraying of Agent
Orange and other herbicides contaminated with
TCDD during the Vietnam War from 1962 to
1971. We selected a subpopulation involving
343 Ranch Hand veterans and determined
TCDD concentrations in blood samples col-
lected every 5 years from 1982 to 1998 for a
total of four or ﬁve samples from each veteran
from this subpopulation (Michalek et al. 2003).
Data from 20 randomly selected subjects from
the Ranch Hand cohort subpopulation were
used to optimize the human PBPK. The second
set of data used to optimize the model was from
Poiger and Schlatter (1986), in which a single
volunteer received a single oral dose of 1.14 ng
TCDD/kg and was followed for 40 days. These
data were used in the optimization of the
absorption and distribution processes occurring
during the initial phase of the exposure.
Our assessment of the human PBPK model
used an additional 10 randomly selected sub-
jects from the Ranch Hand cohort and showed
a good correlation (r2 = 0.995) between pre-
dicted blood concentrations in 1982 and mea-
sured blood concentrations in 1982 (Table 1).
We also assessed the human PBPK model with
a second data set. In the fall of 1997, two
women presented clinical signs of TCDD
intoxication (Geusau et al. 2002). After presen-
tation of chloracne, between the spring of 1998
through 2001, 25 and 20 blood samples were
collected from patients 1 and 2, respectively
(Geusau et al. 2002). These women are among
those with the highest TCDD blood concen-
trations ever measured in adults.
Results
In the veterans of Operation Ranch Hand,
TCDD blood concentrations were ﬁrst deter-
mined starting in 1982 (Michalek et al. 1996,
2002). The exposure occurred between 1962
and 1971, with a typical tour of duty lasting
only a year. Peak blood concentrations were
assumed to occur at the time of discharge from
Vietnam. We documented the time of dis-
charge for each veteran in the Ranch Hand
cohort, and used these individual data in the
back calculation for this study. TCDD blood
concentrations were determined at four or ﬁve
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In epidemiologic studies, exposure assessments of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
assume a ﬁxed elimination rate. Recent data suggest a dose-dependent elimination rate for TCDD. A
physiologically based pharmacokinetic (PBPK) model, which uses a body-burden–dependent elimi-
nation rate, was developed previously in rodents to describe the pharmacokinetics of TCDD and has
been extrapolated to human exposure for this study. Optimizations were performed using data from
a random selection of veterans from the Ranch Hand cohort and data from a human volunteer who
was exposed to TCDD. Assessment of this PBPK model used additional data from the Ranch Hand
cohort and a clinical report of two women exposed to TCDD. This PBPK model suggests that previ-
ous exposure assessments may have signiﬁcantly underestimated peak blood concentrations, resulting
in potential exposure misclassiﬁcations. Application of a PBPK model that incorporates an inducible
elimination of TCDD may improve the exposure assessments in epidemiologic studies of TCDD.
Key words: dioxin, epidemiology, PBPK, pharmacokinetic, physiologically based pharmacokinetic
model, Ranch Hand, risk assessment. Environ Health Perspect 113:1666–1668 (2005).
doi:10.1289/ehp.8016 available via http://dx.doi.org/ [Online 25 August 2005]time points for each Veteran starting in 1982.
For each TCDD measurement we used data
on body weight and height for each individual
to estimate the body mass index for each vet-
eran. We used the body mass index to estimate
size of the adipose tissue compartment at the
time of TCDD measurement for each individ-
ual based on the approach of Deurenberg et al.
(1991). We estimated peak TCDD blood con-
centrations for each individual with the PBPK
model using their individual data on blood
concentrations, adipose tissue mass, and the
time of discharge from Vietnam. We also esti-
mated peak blood concentrations using a clas-
sical one compartment pharmacokinetic model
with a first-order elimination. The classical
model assumed a TCDD half-life of 8.7 years
and used the TCDD blood concentrations at
1982 (Michalek et al. 1996) and the time of
discharge as inputs into the model to estimate
peak blood concentrations.
In 1982, the range of blood concentrations
from 10 randomly chosen subjects, shown in
Table 1, was approximately 16-fold, from 12.7
to 209 ppt. We used a classical pharmaco-
kinetic approach; peak blood concentrations
ranged approximately 12-fold, from 53 to
640 ppt (Table 1). Minor differences in the
ranking and range of TCDD blood concentra-
tions occur when comparing estimated peak
concentrations using the one compartment
classical pharmacokinetic model to blood con-
centrations measured in 1982. When using the
PBPK model to estimate peak blood con-
centrations, we found a much larger range in
exposures and a significant difference in the
exposure rankings (Table 1). The PBPK model
estimates that peak blood concentrations at
the time of discharge range > 250-fold, from
138 to approximately 40,000 ppt. This large
difference is due to the inclusion of a dose-
dependent elimination rate in the PBPK
model. At the lower exposures, the half-life of
TCDD is > 10 years, and at the higher expo-
sures the half-life is only weeks. Models ﬁts to
these data are presented in Figure 1.
The model predictions show good correla-
tions with the measured blood concentrations
in the two highly exposed women (Figure 2).
The model predicts a rapid decrease in the
blood concentrations during the distribution
phase of the ﬁrst few months of exposure, fol-
lowed by an elimination that appears ﬁrst order
at these exposures because of maximal induc-
tion of TCDD sequestration metabolism. The
elimination rates in these women suggest that
the overall half-life of TCDD during the ﬁrst
2 years of exposure is < 3 months. In the ﬁrst
blood samples collected from these women, the
concentrations of TCDD were 144,000 and
26,000 ppt (lipid adjusted) in patient 1 and 2,
respectively (Geusau et al. 2002). The PBPK
model estimates that initial blood concentra-
tions may have been as high as 507,000 ppt
and 87,000 ppt (lipid adjusted) in patients 1
and 2, respectively. Based on this model, maxi-
mum CYP1A2 induction occurs at blood con-
centrations of approximately 1,250 ppt (lipid
adjusted). Measured levels of TCDD in the
women were approximately 20–100 folds
higher than the blood concentrations that are
predicted to be at maximal induction (Geusau
et al. 2002).
Discussion
Studies on the elimination of TCDD have
examined cohorts many years after the expo-
sures and suggest that the half-life approaches
Human dioxin exposures revisited
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Table 1. Comparison of initial blood concentration (Cblood) determination by first-order elimination or by
PBPK model in 10 Ranch Hand veterans.a
Cblood in 1982 Cblood at the time of discharge from Vietnam
Predicted Estimated with Estimated with
Measured with PBPK model constant T1/2 of 8.7 years a PBPK model
Group (pg/g lipid adjusted) (pg/g lipid adjusted) (pg/g lipid adjusted) (pg/g lipid adjusted)
Low 12.7 13.7 53 138
16.7 20.1 44 166
23.5 26.9 72 277
24.6 29.5 112 587
25.0 19.4 83 168
High 33.7 37.8 103 492
43.8 25.5 123 197
115.5 132.3 381 6,622
182.3 198.3 602 40,376
209.7 234.6 640 35,412
T1/2, half-life of TCDD in the blood.
aThe model provides a good prediction of the measured blood concentrations in 1982 with a coefﬁcient of determination
of R2 = 0.995.
Figure 1. Model predictions of TCDD blood concentration in 10 veterans (A–J) from the Ranch Hand cohort.
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a decade. However, these studies did not
examine the initial elimination of TCDD
immediately after high-level exposures. The
high concentration predicted with the model
during the ﬁrst 6 months is an extrapolation
of what should be the concentration at the
time of initial exposure. Limited data are
available to validate the model for the initial
exposure period. One data set is available
from Poiger and Schlatter (1986). Although
these data were used in the optimization of the
model, the small sample size and only a single
dose level do not provide conﬁdence that the
data from Poiger and Schlatter (1986) repre-
sent the wide range of potential exposures and
populations at risk.
A number of pharmacokinetic models
have incorporated dose-dependent elimination
of TCDD. These models use a variety of
approaches to describe the dose dependency.
Andersen et al. (1993) use a hyperbolic func-
tion related to receptor occupancy to describe
the dose-dependent elimination. This func-
tion is modified by a species specific “fold”
factor that is used to adjust the elimination
rate. In rats this factor is 1 and allows for a
doubling of the elimination rate; other species
would have different adjustment factors. Kohn
et al. (2001) also use a Hill equation for the
kinetics of the metabolizing enzyme with
cytosolic TCDD concentrations as the sub-
strate concentration. TCDD is also hypothe-
sized to be eliminated through biliary
pathways after hepatocyte lysis at high expo-
sures in the model of Kohn et al. (2001). In
the models of Carrier et al. (1995a, 1995b)
and Aylward et al. (2005), the elimination of
TCDD is described as a function of total
hepatic TCDD concentrations. The elimina-
tion of TCDD in these models is dose depen-
dent because there is a dose-dependent
sequestration of TCDD in the liver. In the
present model we describe the elimination rate
as a function of CYP1A2 induction. The dif-
ferent approaches used to describe the dose-
dependent induction of TCDD elimination
are due to a lack of understanding of the bio-
logic basis of these phenomena. This uncer-
tainty in our understanding of the elimination
of TCDD indicates that caution should be
used when applying any of these models to
human epidemiologic studies. However, the
use of dose-dependent elimination of TCDD
is an important concept to consider when
choosing and applying pharmacokinetic tools
in exposure assessments for dioxin.
Recent studies that measured TCDD
blood concentrations shortly after high-level
exposure indicate that the half-life is dose
dependent (Geusau et al. 2002), as do clinical
studies of the Ranch Hand cohort (Michalek
et al. 2002). The use of ﬁrst-order elimination
of TCDD could significantly underestimate
past exposures, resulting in exposure misclassi-
ﬁcations in the epidemiologic studies. Using a
PBPK model that incorporates a dynamic
elimination rate may provide a more accurate
assessment of past exposures in the epidemio-
logic studies. A better understanding of the
biologic basis of the dose-dependent elimina-
tion of TCDD would allow for the develop-
ment of more biologically realistic PBPK
models. Further validation of this model is
required before use in a quantitative exposure
assessment. However, a pharmacokinetic
model that includes an inducible elimination
should be applied when assessing past expo-
sures to TCDD.
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Patient 1
Patient 2Over the last two decades, atmospheric concen-
trations of lead have decreased significantly
around the globe as more and more nations
have chosen to remove tetraethylead from gaso-
line (Thomas et al. 1999). However, humans
may also be exposed to Pb through contami-
nated food, water, and house dust and through
industrial activities such as metal recycling and
the battery industry. In the United States, for
example, although the use of Pb in house paint
peaked in 1940 and was banned in 1978, 40%
of the nation’s housing stock is estimated to
still contain Pb-based paint (Wakeﬁeld 2002).
After Pb enters the body, it can travel
along several pathways depending on its source
and, by extension, its bioavailability. The frac-
tion of Pb that is absorbed depends mainly on
the physical and chemical form, particularly
particle size and the solubility of the speciﬁc
compound. Other important factors are spe-
ciﬁc to the exposed subject, such as age, sex,
nutritional status and, possibly, genetic back-
ground [Agency for Toxic Substances and
Disease Registry (ATSDR) 1999; National
Research Council 1993]. One of the earliest
toxicokinetics studies reported that Pb, once
absorbed into the blood compartment, has a
mean biological half-life of about 40 days in
adult males(Rabinowitz et al. 1976). The half-
life in children and in pregnant women was
reported to be longer, because of bone remod-
eling (Gulson et al. 1996; Manton et al. 2000).
However, another study was unable to conﬁrm
this ﬁnding (Succop et al. 1998).
Like many other “bone-seeking” elements,
Pb from blood is incorporated into calciﬁed tis-
sues such as bone and teeth, where it can
remain for years(Rabinowitz 1991; O´Flaherty
1995). According to Rabinowitz (1991), the
half-life of Pb in bone (bone-Pb) ranges from
10 to 30 years. However, the use of the term
“half-life” to describe the biological clearance of
Pb from bone implicitly makes assumptions
about the kinetics of the process by which Pb is
released. Some researchers prefer to use the
term “residence time” to avoid implying more
precision than what can be directly determined
(Chettle D, personal communication). From
calcified tissue stores, Pb is slowly released,
depending on bone turnover rates, which in
turn are a function of the type of bone, whether
compact (slow turnover) or trabecular (rapid
turnover) (O´Flaherty 1995). Brito et al.
(2002) reported that the release rate of Pb from
bone varies with age and intensity of exposure.
Brito et al. (2005) also examined estimates of
exchange rates among compartments. The
transfer of Pb from blood to other compart-
ments was much more rapid than the 1-month
estimate reported previously (Brito et al. 2005),
with the overall clearance rate from blood (sum
of rates from blood to cortical bone, to trabecu-
lar bone and to other tissue), implying a half-
life of 10−12 days (Brito et al. 2005). This
highlights the difference between the overall
clearance viewed from outside, when no
allowance can be made for recirculation, and
actual transfer rates.
Physiologic differences between children
and adults account for much of the increased
susceptibility of small children to the deleteri-
ous effects of Pb: whereas in adults 94% of Pb
body burden is stored in bones and teeth, this
proportion is only 70% in children (Barry
1981). In addition, the continuous growth of
young children implies constant bone remod-
eling for skeletal development (O´Flaherty
1995). This contributes to a state in which Pb
stored in bone is continually released back into
the blood compartment, a process that has
been described as “endogenous contamina-
tion” (Gulson et al. 1996). This process is par-
ticularly significant for pregnant women
because pregnancy causes an increase in bone
remodeling. The apparently limited success of
various Pb hazard control measures in decreas-
ing blood Pb (BPb) levels in exposed children
and pregnant women may reflect a constant
bone resorption process (Rust et al. 1999).
Popovic et al. (2005) recently reported very
different long-term Pb kinetics between men
and women, with premenopausal women
appearing to retain Pb more avidly or release
Pb more slowly compared to postmenopausal
women and to men.
Biomonitoring Human
Exposure to Lead
Biomonitoring for human exposure to Pb
reﬂects an individual’s current body burden,
which is a function of recent and/or past
exposure. Thus, the appropriate selection and
measurement of biomarkers of Pb exposure is
of critical importance for health care manage-
ment purposes, public health decision
making, and primary prevention activities.
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Lead concentration in whole blood (BPb) is the primary biomarker used to monitor exposure to this
metallic element. The U.S. Centers for Disease Control and Prevention and the World Health
Organization deﬁne a BPb of 10 µg/dL (0.48 µmol/L) as the threshold of concern in young children.
However, recent studies have reported the possibility of adverse health effects, including intellectual
impairment in young children, at BPb levels < 10 µg/dL, suggesting that there is no safe level of expo-
sure. It appears impossible to differentiate between low-level chronic Pb exposure and a high-level
short Pb exposure based on a single BPb measurement; therefore, serial BPb measurements offer a
better estimation of possible health outcomes. The difﬁculty in assessing the exact nature of Pb expo-
sure is dependent not so much on problems with current analytical methodologies, but rather on the
complex toxicokinetics of Pb within various body compartments (i.e., cycling of Pb between bone,
blood, and soft tissues). If we are to differentiate more effectively between Pb stored in the body for
years and Pb from recent exposure, information on other biomarkers of exposure may be needed.
None of the current biomarkers of internal Pb dose have yet been accepted by the scientiﬁc commu-
nity as a reliable substitute for a BPb measurement. This review focuses on the limitations of bio-
markers of Pb exposure and the need to improve the accuracy of their measurement. We present here
only the traditional analytical protocols in current use, and we attempt to assess the inﬂuence of con-
founding variables on BPb levels. Finally, we discuss the interpretation of BPb data with respect to
both external and endogenous Pb exposure, past or recent exposure, as well as the signiﬁcance of Pb
determinations in human specimens including hair, nails, saliva, bone, blood (plasma, whole blood),
urine, feces, and exfoliated teeth. Key words: biomarkers, biomonitoring, blood, bone, feces, hair, lead,
plasma, saliva, teeth, toxicokinetics, urine. Environ Health Perspect 113:1669–1674 (2005).
doi:10.1289/ehp.7917 available via http://dx.doi.org/ [Online 11 August 2005]It is well known that Pb affects several enzy-
matic processes responsible for heme synthesis.
Lead directly inhibits the activity of the cyto-
plasmic enzyme δ-aminolevulinic acid dehy-
dratase (ALAD), resulting in a negative
exponential relationship between ALAD and
BPb. Pb depresses coproporphyrinogen oxidase,
resulting in increased coproporphyrin activity.
Pb also interferes with the normal functioning
of the intramitochondrial enzyme ferro-
chelatase, which is responsible for the chelation
of iron by protoporphyrin. Failure to insert Fe
into the protoporphyrin ring results in
depressed heme formation and an accumula-
tion of protoporphyrin; this in turn chelates
zinc in place of Fe, to form zinc proto-
porphyrin. These effects also result in modiﬁca-
tions of some other metabolite concentrations
in urine (ALA-U), blood, (ALA-B) and plasma
(ALA-P), coproporphyrin in urine (CP). The
activities of pyrimidine nucleotidase (P5´N)
and nicotinamide adenine dinucleotide syn-
thase (NADS) are also modiﬁed in blood after
Pb exposure. Levels of these various metabolites
in biological ﬂuids have been used in the past to
diagnose Pb poisoning when direct Pb levels
were difﬁcult to obtain in tissues or body ﬂuids
(Leung et al. 1993) or as information comple-
mentary to BPb test results. They are more
accurately described as biomarkers for toxic
effects of Pb. In this review we focus on mark-
ers that are more accurately deﬁned as biomark-
ers of Pb exposure, namely, Pb concentrations
in biological tissues and ﬂuids. Biomarkers for
the toxic effects of Pb have been reviewed in
some detail elsewhere (Sakai 2000).
Throughout the last five decades, whole
blood has been the primary biological fluid
used for assessment of Pb exposure, both for
screening and diagnostic purposes and for bio-
monitoring purposes in the long term.
Although BPb measurements reflect recent
exposure, they may also represent past expo-
sures, as a result of Pb mobilization from bone
back into blood (Gulson et al. 1996). In those
subjects without excessive exposure to Pb,
45–75% of the Pb in blood may have come
from bone (Gulson et al. 1995; Smith et al.
1996). In exposed children, however, it has
been reported that the bone-Pb contribution
to blood can be 90% or more (Gwiazda et al.
2005). Thus, reductions in BPb levels after
environmental Pb remediation may be
buffered somewhat by contributions from
endogenous Pb sources (Lowry et al. 2004;
Rust et al. 1999). Remediation efforts typically
result in reductions of BPb levels in exposed
children of no more than 30%, when evalu-
ated within several months after intervention
(U.S. Enviromental Protection Agency 1995).
Roberts et al. (2001) reported that in children
with BPb levels between 25 and 29 µg/dL who
were not treated with chelation drugs, the time
required for BPb to decline to < 10 µg/dL is
about 2 years. Some researchers have suggested
that the efficacy of Pb hazard remediation
efforts should be evaluated over extended peri-
ods to allow adequate time for mobilization
and depletion of accumulated skeletal Pb stores
and to allow a reduction in the absolute contri-
bution to BPb levels from these stores
(Gwiazda et al. 2005; Lowry et al. 2004).
Thus, the mean of serial BPb levels should be a
more accurate index of long-term Pb exposure.
Data collected as part of the U.S. National
Health and Examination Survey (NHANES)
give the 95th percentile for BPb as 7.0 µg/dL
for children 1−5 years of age and as 5.20 µg/dL
for adults 20 years of age and older [U.S.
Centers for Disease Control and Prevention
(CDC) 2003]. Although the BPb levels of U.S.
populations have dropped markedly compared
to 30 years ago, new concerns have been raised
regarding possible adverse health effects in chil-
dren at BPb levels < 10 µg/dL; perhaps there is
no safe threshold but, rather, a continuum of
toxic effects (Canﬁeld et al. 2003). In light of
these concerns, the CDC Advisory Committee
on Childhood Lead Poisoning Prevention
formed a working group to review the evidence
for adverse health effects at BPb levels
< 10 µg/dL in children. Although this working
group concluded that several studies in the lit-
erature had demonstrated a statistically signiﬁ-
cant association between BPb levels < 10 µg/dL
and some adverse health effects in children, the
effects were very small and could conceivably
have been inﬂuenced by residual confounding
factors. The working group’s report called for
further studies to examine the relationship
between lower BPb levels and health outcomes
to provide a more complete understanding of
this issue (CDC 2004).
Many studies have reported statistically sig-
nificant associations between BPb levels and
various health effect outcomes. Some, however,
have been statistically weak, with the magni-
tude of the effect relatively small. According to
Hu et al. (1998), such weaknesses of associa-
tion may occur because BPb is not a suffi-
ciently sensitive biomarker of exposure or dose
at the target organ(s) or because the relation-
ships involved are biologically irrelevant and
are only found because of an uncontrolled con-
founding factor. Furthermore, in view of the
kinetics of Pb distribution within the body
(cycling among blood, bone, and soft tissues),
differentiation of low-level chronic exposure
from a short high-level exposure is not possible
on the basis of a single BPb measurement (Hu
et al. 1998). Consequently, there is renewed
interest in alternative biomarkers that may aid
diagnosis of the extent of Pb exposure. Such
alternatives include Pb determinations in
plasma/serum, saliva, bone, teeth, feces, and
urine. However, none of these matrices has
gained convincing acceptance as an alternative
to BPb. This is partly due to data based on
erroneous or dubious analytical protocols that
do not consider the confounding variables.
Plasma/Serum Lead
Plasma-Pb likely represents a more relevant
index of exposure to, distribution of, and
health risks associated with Pb than does BPb.
Indeed, from a physiologic point of view, we
can assume that the toxic effects of Pb are pri-
marily associated with plasma-Pb because this
fraction is the most rapidly exchangeable one
in the blood compartment. In recent years
increased attention has been paid to monitor-
ing the concentration of Pb in plasma (or
serum). However, research on associations
between plasma-Pb and toxicologic outcomes
is still sparse, and a signiﬁcant gap in knowl-
edge remains.
Plasma/serum Pb levels in nonexposed and
exposed individuals reported in older publica-
tions range widely, from 0.02 to 14.5 µg/L
(Versieck and Cornelis 1988). This is proba-
bly due to inappropriate collection methods,
analytical instrumentation, and methods for
Pb determination. The development and use
of more sensitive analytical instrumentation,
especially inductively coupled plasma mass
spectrometry (ICP-MS), has resulted in deter-
minations of Pb in plasma and serum speci-
mens with much lower detection limits and
with better accuracy. More recent data, also
based on ICP-MS methods, have shown
plasma-Pb levels < 1.0 µg/L in nonexposed
individuals (Schutz et al. 1996).
The use of advanced analytical techniques
is not the only essential requirement to ensure
accurate and reliable plasma-Pb data.
Contamination of the specimen may occur at
the preanalytical phase, namely, during collec-
tion, manipulation, or storage. Use of
Class-100 biosafety cabinets and clean rooms
for specimen preparation and analysis is
mandatory. Moreover, all analytical reagents
used must be of the highest purity grade.
These conditions are far more rigorous than
are typically required for clinical BPb measure-
ments performed in a commercial laboratory.
After the blood specimen has been collected,
the serum/plasma separation must be per-
formed as soon as possible because there is
high potential for Pb to move from the domi-
nant BPb subcompartment repository,
namely, the erythrocytes, into the plasma via
hemolysis, leading to erroneously high results
for plasma-Pb. Plasma hemolysis can be esti-
mated by analyzing hemoglobin levels in the
specimen because these levels are likely to
become abnormally elevated with hemolysis
(Smith et al. 2002). Materials for specimen
collection and storage and the anticoagulant
must be of the highest quality because these
can be another source of Pb contamination.
Commercial evacuated blood tubes, pre-
pared speciﬁcally for BPb measurements, are
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et al. 1999), but it is nevertheless desirable for
the analyzing laboratory to characterize the
background Pb contamination in each new lot
of tubes to ensure that reported concentrations
are not compromised by contamination. The
choice of anticoagulant is important because
EDTA, as a strong metal-chelating agent, may
be difficult to obtain without some back-
ground contamination and may give mislead-
ingly high plasma-Pb results because of
selective extraction of Pb bound to erythro-
cytes. The use of heparin is problematic
because heparinized blood is more prone to
form fibrin clots after several hours. These
issues were evaluated by Smith et al. (1998) in
some detail; they compared commercial
Vacutainer-type tubes with ultracleaned collec-
tion tubes containing either EDTA or heparin.
As there are no commercial blood collection
tubes available that are certiﬁed for ultra-low
Pb measurements, the analyzing laboratory
should prepare precleaned polyethylene tubes
containing ultra low-Pb anticoagulants.
There are many reports of plasma-Pb
measurements where validation data are either
weak or absent. For example, some simply cite
successful participation of the analyzing labora-
tory in quality assurance (QA) programs for
whole blood Pb operated by the CDC and the
College of American Pathologists (Hernandez-
Avila et al. 1998), whereas others neglect to
cite any kind of QA program (Dombovari
et al. 2001). Participation in QA schemes
designed specifically for whole BPb, while
commendable, does not address the much
more challenging analysis for plasma-Pb. This
problem is compounded by the lack of certi-
fied reference materials for either serum or
plasma-Pb (Cake et al. 1996). For these rea-
sons, production of plasma or serum reference
materials that have Pb concentrations certiﬁed
close to current human values is urgently
needed to support method validation.
Saliva Lead
Saliva has been proposed as a diagnostic
specimen for various purposes, as it is easily
collected (Silbergeld 1993). However, in the
absence of consistent and dependable saliva Pb
measurements, it is not generally accepted as a
reliable biomarker of Pb exposure. Saliva shows
large variations in its ion content throughout
the day, coupled with changes in salivary ﬂow
rates before, during, and after meals. Variations
also arise depending on the manner in which
saliva collection is stimulated (or not) and
on the nutritional and hormonal status of
the individual.
Some data suggest an association between
Pb levels in saliva and those in either plasma or
blood (Omokhodion and Crockford 1991;
Pan 1981). Moreover, it has been argued that
Pb in saliva is the direct excretion of the Pb
fraction in diffusible plasma namely, the frac-
tion not bound to proteins) (Omokhodion
and Crockford 1991). Despite the associations
reported in the literature, the older saliva Pb
concentrations are quite high, and the values
vary among studies. Recent data suggest much
lower saliva Pb levels, in both exposed and
unexposed subjects (Koh et al. 2003; Wilhelm
et al. 2002). According to Wilhelm et al.
(2002), Pb content in the saliva of unexposed
children is usually < 0.15 µg/dL.
Uncontrolled variation in salivary flow
rates, lack of standard or certified reference
materials, and absence of reliable reference val-
ues for human populations are major factors
that limit the utility of saliva Pb measurements.
In addition the very low levels of Pb present in
saliva limit the range of suitable analytical tech-
niques, thereby further diminishing the utility
and reliability of this biomarker for evaluating
Pb exposure.
Hair Lead 
Hair is a biological specimen that is easily and
noninvasively collected, with minimal cost,
and it is easily stored and transported to the
laboratory for analysis. These attributes make
hair an attractive biomonitoring substrate, at
least superficially. Because Pb is excreted in
hair, many have suggested it for assessing Pb
exposure, particularly in developing countries
where specialized laboratory services may
be unavailable and resources are limited
(Schumacher et al. 1991). However, an exten-
sive debate is ongoing about the limitations of
hair as a biomarker of metal exposure gener-
ally. Here we limit our discussion to Pb expo-
sure, although many of the issues for Pb, such
as preanalytical concerns for contamination
control, sampling, and reference ranges, also
apply to other metals.
The ability to distinguish between Pb that
is endogenous, namely, absorbed into the blood
and incorporated into the hair matrix, and Pb
that is exogenous, namely, derived from exter-
nal contamination, is a major problem. During
the washing step it is assumed that exogenous
Pb is completely removed, whereas endogenous
Pb is not. However, no consensus exists about
how removal of exogenous Pb is best accom-
plished. Some publications that describe the use
of hair for assessing Pb exposure reference a hair
washing method proposed by the International
Atomic Energy Agency (IAEA) in 1978. The
approach entailed washing hair specimens with
acetone/water/acetone (Ryabukin 1978).
However, a recent study (Morton et al. 2002)
demonstrated that the IAEA method failed to
remove exogenous Pb from hair.
Another issue is the signiﬁcant variation in
the Pb concentration profile among various
subpopulations according to age, sex, hair
color, and smoking status (Wolfsperger et al.
1994). Moreover, geographic, racial/ethnic,
and ecologic factors can also affect Pb distribu-
tion in hair within a given population. Thus, it
is difﬁcult to establish reference ranges because
confounding factors impose restrictions on the
interpretation of individual results. No consen-
sus exists on the length of the hair specimen to
be collected, or the amount, or the position on
scalp. Variations in Pb content between single
hairs from the same individual can be as high
as ± 100%, particularly in the distal region
(Renshaw et al.1976).
Recently, the ATSDR established an expert
advisory panel to review current knowledge
about the use of hair analysis for trace metals in
biomonitoring (ATSDR 2001). The general
consensus was that many scientiﬁc issues need
to be resolved before hair analysis can become
a useful tool in understanding environmental
exposures. Although hair analysis may be able
to answer some speciﬁc questions about envi-
ronmental exposure to a few substances, it
often raises more questions than it answers.
The scientiﬁc community currently does not
know the range of Pb contamination levels
typically found in human hair. Without reli-
able data on baseline or background hair con-
tamination levels in the general population,
health agencies cannot determine whether
results from a given site are unusually high or
low (ATSDR 2001).
In addition to the preanalytical issues and
the absence of reliable reference ranges, the
quality of analytical techniques used for deter-
mining Pb, as well as other trace metals, in hair
has been questioned. In a recent interlaboratory
study of commercial laboratories that speciﬁ-
cally market the test for trace metals in hair,
interlaboratory agreement was judged very
poor, with wide discrepancies observed for Pb
as well as for other elements (Seidel et al. 2001).
Urinary and Fecal Lead
The determination of Pb in urine (urine-Pb) is
considered to reﬂect Pb that has diffused from
plasma and is excreted through the kidneys.
Collection of urine for Pb measurements is
noninvasive and is favored for long-term bio-
monitoring, especially for occupational expo-
sures. However, a spot urine specimen is
particularly unreliable because it is subject to
large biological variations that necessitate a cre-
atinine excretion correction. Urine-Pb origi-
nates from plasma-Pb that is filtered at the
glomerular level; thus, according to some
authors (Tsaih et al. 1999), urine-Pb levels that
are adjusted for glomerular ﬁltration rate may
serve as a proxy for plasma-Pb. Hirata et al.
(1995) found a better correlation between the
concentration of plasma-Pb and urine-Pb than
between BPb and urine-Pb for lead workers
with low levels of Pb exposure. Manton et al.
(2000), using high-precision Pb isotope ratio
measurements, found the concentration of
urine-Pb to be about 10% of that in whole
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ticularly robust. In contrast, correlations with
isotopic ratios were excellent. According to
Tsaih et al. (1999), cortical bone contributes a
mean of 0.43 µg Pb per day excreted in urine,
whereas trabecular bone contributes as much as
1.6 µg Pb per day. Cavalleri et al. (1983)
observed different Pb kinetics between exposed
and nonexposed subjects after the administra-
tion of CaNa2EDTA. In unexposed subjects
BPb levels remained stable even after 5 hr of
CaNa2EDTA administration. However,
plasma-Pb levels in the unexposed group
decreased by as much as one half, while
urine-Pb increased by a factor of 10. In the Pb-
exposed group the same amount of chelation
therapy resulted in plasma-Pb levels increasing
by a factor of 2, while BPb levels decreased by a
factor of 2, with a higher urine-Pb excretion.
Thus, it seems that in nonexposed subjects a
major contribution for urine-Pb is derived from
the Pb fraction in soft tissues that is in equilib-
rium with that in plasma compartment. We
could speculate that the larger the amount of
erythrocyte-bound Pb, the weaker the binding
forces, and that a signiﬁcant fraction of Pb is
released from red blood cell membranes into
plasma and is then filtered by the kidney.
Because the amount of Pb excreted is very high,
the kidneys are unable to remove it rapidly
from the blood stream; this may account for the
temporal elevation of plasma-Pb levels.
The availability of reliable urine quality-
control materials and reference materials certi-
fied for Pb content and participation in
external quality assessment schemes for
urine-Pb are important factors in assuring the
accuracy of analytical results. However, the
tendency for urate salts to precipitate out of
urine during transit and storage can be a com-
plicating factor in the analysis. Moreover,
because only a few studies have examined asso-
ciations between urine-Pb and other biomark-
ers, the use of urine-Pb measurements is
essentially limited to long-term occupational
monitoring programs, monitoring patients
during chelation-therapy, and, until very
recently, to clinical evaluation of potential can-
didates for chelation therapy.
Measurement of fecal-Pb content over sev-
eral days is one possible approach to estimating
the overall magnitude of childhood Pb intake.
According to Gwiazda et al. (2005), fecal-Pb
content should give an integrated measure of
Pb exposure/intake from all sources, dietary
and environmental, inside and outside the
home (by isotopic composition). However, a
limitation to the use of fecal-Pb is that the col-
lection of complete fecal samples over multiple
days may not be feasible. As stated by Gwiazda
et al. (2005), fecal-Pb reflects unabsorbed,
ingested Pb plus Pb that is eliminated via
endogenous fecal (biliary) routes; interindivid-
ual variations in these physiologic processes
may show up as variation that is wrongly
attributable to environmental Pb exposure.
Nail Lead
Like hair, nails have many superﬁcial advan-
tages as a biomarker for Pb exposure, especially
because specimen collection is noninvasive and
simple and because nail specimens are very sta-
ble after collection, not requiring special stor-
age conditions. Nail-Pb is considered to reﬂect
long-term exposure because this compartment
remains isolated from other metabolic activities
in the body (Takagi et al. 1988). Because toe-
nails are less affected by exogenous environ-
mental contamination than fingernails, they
have been preferred for Pb exposure studies.
Toenails have a slower growth rate than ﬁnger-
nails (up to 50% slower, especially in winter)
and thus may provide a longer integration of
Pb exposure.
Lead concentration in nails depends on
the subject’s age (Nowak and Chmielnicka
2000), but it seems not to depend on the sub-
ject’s sex (Rodushkin and Axelsson 2000). 
Gulson (1996a) reported high variability
in Pb levels measured in the same ﬁngernails
and toenails of various subjects, even after rig-
orous washing procedures; such lack of repro-
ducibility suggests that nail specimens offer
only limited scope in assessing exposure to Pb.
Bone Lead
Because bone accounts for > 94% of the
adult body burden of Pb (70% in children)
(O´Flaherty 1995), many researchers accept
that a cumulative measure of Pb dose may be
the most important determinant of some forms
of toxicity (cumulative measure means an
exposure that is integrated over many years,
rather than based on a single BPb measure-
ment) (Landrigan and Todd 1994; Hu et al.
1998). In support of this hypothesis, recent
studies have shown that bone-Pb but not BPb
is signiﬁcantly related to declines in hematocrit
and hemoglobin among moderately Pb-
exposed construction workers and to decreased
birth weight and increased odds of clinically
relevant hypertension (Gonzalez-Cossio et al.
1997; Hu et al. 1996). According to Hu et al.
(1998), other adverse health outcomes likely to
be associated with bone-Pb levels include
impairment of cognitive performance and
growth in children and kidney failure, gout,
elevated blood pressure, reproductive toxicity,
and adverse cardiovascular events in adults.
As pointed by Hu et al. (1998), two major
paradigms relate to skeletal Pb: bone-Pb as an
indicator of cumulative Pb exposure (bone-Pb
as a repository), and bone-Pb as a source of
body burden that can mobilized into the circu-
lation (bone-Pb as a source). Hernandez-Avila
et al. (1998) reported a strong association
between bone-Pb levels and serum-Pb levels of
adults exposed to Pb. That study indicated the
potential role of the skeleton as an important
source of endogenous, labile Pb that may not
be adequately discerned through measurement
of BPb levels. The same authors argued that
skeletal sources of Pb accumulated from past
exposures should be considered along with cur-
rent sources when exposure pathways are being
evaluated. In an attempt to characterize the
source of Pb exposure, Gulson et al. (1995)
measured the 206Pb/204Pb isotopic ratios in
immigrant Australian subjects, Australian-born
subjects, and environmental samples. The
immigrant population exhibited Pb isotopic
ratios from 17.7 to 18.5, distinct from the ratio
in Australian-born subjects (~ 17.0). This dif-
ference allowed a distinction to be drawn
between current exposure acquired from
Australian sources and older bone-stored Pb
that was not acquired from Australian sources.
Differing bone types have differing
bone-Pb mobilization characteristics. For exam-
ple, the tibia principally consists of cortical
bone, whereas the patella is largely trabecular
bone. Pb in trabecular bone is more biologi-
cally active than Pb in cortical bone, and tra-
becular bone has a shorter turnover time. The
endogenous contribution of Pb from bone
stores is an important health consideration.
The O´Flaherty kinetic model can be used to
indicate the quantity of Pb delivered from bone
as a function of bone turnover and Pb exchange
(O´Flaherty 1995). A recent revision of this
model (Fleming et al. 1999) suggests that a
smeltery worker with a tibia Pb concentration
of 100 µg/g can expect a continuous endoge-
nous contribution to BPb of 16 µg/dL. A preg-
nant woman with a tibia Pb concentration of
50 µg/g can end up with a contribution of
8 µg/dL BPb; this ﬁgure does not consider the
increased rate of bone turnover associated with
pregnancy. Individuals not exposed to Pb in the
workplace typically display tibia Pb levels up to
about 20 µg/g (Roy et al. 1997).
Over the last decade bone-Pb measure-
ments based on noninvasive in vivo X-ray ﬂuo-
rescence (XRF) methods have become
increasingly accepted. The technique uses ﬂuo-
rescing photons to remove an inner-shell elec-
tron from a Pb atom, leaving it in an excited
state. The result is emission of X-ray photons
that are characteristic of Pb. Measurements are
performed by using one of four kinds of XRF:
two involve fluorescence of the K-shell elec-
trons of Pb (K-XRF), and the other two
involve fluorescence of the L-shell electrons
(L-XRF) (Todd et al. 2002a). Several groups,
mainly in North America, have reported the
development of in vivo measurement systems;
the majority have adopted the K-XRF
approach based on excitation with a 109Cd iso-
tope and backscatter geometry because of its
advantages: it provides a robust measurement
with a better detection limit and a lower effec-
tive (radiation) dose (as compared to L-XRF)
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is not a limiting factor in using this technique
with humans, as demonstrated by Todd and
Chettle (1994).
Calibration is usually performed with Pb-
doped plaster-of-Paris phantoms (Todd et al.
2002a). Method accuracy has been evaluated
through comparison of XRF data from cadaver
specimens with electrothermal atomic absorp-
tion spectrophotometry data (Todd et al.
2002b). However, XRF sensitivity and preci-
sion for Pb still constitute an analytical chal-
lenge. In addition to sample-to-sample
reproducibility, XRF can also display a certain
amount of imprecision associated with each
calculated bone-Pb value (Ambrose et al.
2000). This uncertainty, estimated using a
goodness-of-ﬁt statistic from the curve ﬁtting
of the background, ranged from 3 to 30 µg/g
Pb; clearly, this represents a problem for meas-
urements of low-level Pb namely, young chil-
dren and nonexposed populations. Another
problem inherent to the XRF technique is
photon scattering due to overlying tissue or
subject movement during the measurement
period (Ambrose et al. 2000). Normalization
of the Pb signal to the calcium backscatter sig-
nal appears to solve this problem. Precision
depends on the amount of tissue overlying the
bone: the greater the thickness of tissue, the
poorer the precision. Todd and Chettle
(1994), comparing the K-shell with L-shell
precisions with 3 and 6 mm of overlying soft
tissue, reported that K-XRF precision worsens
by only 5%, whereas L-XRF precision worsens
by 49% for greater thickness. The precision of
the L-XRF method is much more severely
affected by the strong attenuation of the
Pb L-shell X rays.
Todd et al. (2001) reported contiguous
inhomogeneities in the distribution of Pb
toward the proximal and distal ends of the tibia
bones. They speculated that the region of
lower Pb concentration has lower blood ﬂow
in the Haversian canals and, consequently, less
Pb available for uptake into bone matrix dur-
ing bone remodeling (Todd et al. 2001).
Trabecular bone has a larger surface area and a
greater volume of blood delivered per unit of
time compared to cortical bone. In addition
there are more active osteons per gram in tra-
becular bone to accomplish resorption and
deposition. Hernandez-Avila et al. (1998)
reported that, in individuals with no history to
occupational Pb exposure, bone-Pb (in particu-
lar trabecular Pb) exerts an additional indepen-
dent influence on plasma-Pb after control
for BPb.
Thus, an appropriate selection of the pre-
cise bone type to be analyzed for Pb content
must be made before commencing. Moreover,
further research on the relationship between
various bone-Pb subcompartments and other
Pb measures is warranted.
Tooth Lead
Like bone, teeth accumulate Pb over the long
term. However, there is some evidence that
teeth are superior to bone as an indicator of
cumulative Pb exposure because the losses
from teeth are much slower (Maneakrichten
et al. 1991). Moreover, deciduous teeth are
relatively easy to collect and analyze; exfoliation
generally occurs after the age of 6 years. Teeth
are also very stable for preservation purposes.
Chronic Pb exposure from mouthing activ-
ity in early childhood may be camouﬂaged by
“dilution” effects during periods of rapid skele-
tal growth in young children and adolescents
and may not be detected by a single BPb meas-
urement. However, most published data on
tooth-Pb have been based on whole tooth
analysis, with no attempt to distinguish among
tooth types (different teeth are formed at dif-
ferent ages) or to differentiate the Pb concen-
tration in enamel from that in dentin (enamel
contains much more Pb, by mass, than does
dentin). The inﬂuence of age and/or sex have
also not been considered (Brown et al. 2002).
Furthermore, use of deciduous teeth is only
possible for children over 6 years in age.
Recently, Gomes et al. (2004) proposed a
solution to the limitations mentioned above
by using an in vivo enamel biopsy of children.
In this approach superficial minerals are
leached from teeth and Pb is determined by
electrothermal atomic absorption spectro-
photometry. One important drawback to this
approach is that, because an accumulation
gradient for Pb has not yet been established
for enamel, only biopsies of a given depth can
be compared to one another. Another issue
related to tooth-Pb measurements is whether
Pb that accumulates in the ﬁrst few microme-
ters of the enamel surface was incorporated
posteruptively (e.g., from the mouth, saliva,
food) rather than during the period when the
tooth was mineralized inside the bone.
An interesting and potentially valuable
aspect of tooth-Pb measurements is their
capacity to elucidate the history of Pb expo-
sure. Teeth are composed of several distinct tis-
sues formed over a period of several years, and
different parts of the tooth can bind Pb at dif-
ferent stages of the individual’s life. Therefore,
a section of tooth can yield historical informa-
tion on the individual’s exposure to Pb. For
example, the enamel of all primary teeth, and
parts of the enamel from some permanent
teeth, are formed in utero and thus may pro-
vide information on prenatal exposure to Pb.
This information could be valuable in improv-
ing our understanding of dose−effect relation-
ships for embryonic anomalies, particularly
neurotoxic dysfunction. The dentine of the
primary teeth provides evidence of exposure
during the early childhood years, when
hand-to-mouth activity is usually an important
contributor to Pb body burden (Gulson
1996b). However, enamel Pb levels may be
useful for indirectly estimating the Pb compo-
sition of the mother’s bone (Gulson 1996b).
More recently there has been some inter-
est in using laser ablation ICP-MS to examine
Pb distribution in tooth profiles. This
approach offers spatially resolved measure-
ments of trace element distribution that can
be compared to a temporal axis via reference
to the neonatal line, enabling researchers to
use not only the Pb concentration of the
entire tooth but also the specific amount of
Pb in each tooth layer, namely, a time line of
Pb exposure. Nevertheless, some serious chal-
lenges remain before this technique can be
fully exploited (Uryu et al. 2003).
Conclusions
Thus far an impressive body of data has been
established based on the use of alternative bio-
markers for monitoring exposure to Pb.
However, it is still unclear to what extent such
data are superior to the information obtained
from BPb measurements. Clearly, many of the
limitations identiﬁed in the foregoing sections
must be resolved before alternative biomarkers
can be accepted as superior indicators of Pb
exposure. At this time BPb measurements are
still the most reliable indicator of recent Pb
exposure, although serial BPb measurements
may offer a better assessment of temporal ﬂuc-
tuations in Pb absorption. If reliable and repro-
ducible plasma-Pb measurements can be
obtained, these may offer better correlation
with toxic effects. However, we do not yet
know what a single plasma-Pb value means, in
terms of health effects; in the absence of a nor-
mal reference range, the clinical utility for indi-
vidual assessment is problematic. Further
research on this issue is needed, especially for
children and adults with low to moderate Pb
exposure. Further efforts are also warranted in
the further development and continued use of
well-established analytical protocols, as well as
in the estimation of random and systematic
errors. Efforts are needed to create regional ref-
erence ranges of nonexposed populations for
each biomarker, to acquire data related to long-
term and short-term exposures, and to evaluate
the inﬂuence of nutritional status and ethnicity
(genetic polymorphisms).
A critical question that might be asked
with respect to an individual’s bone-Pb meas-
urement is what does it mean in terms of
health risk or, perhaps, clinical management?
To answer this question, we may need to dis-
tinguish between bone-Pb measurements in
children and pregnant women, namely, those
with high bone turnover rate compared to
(nonpregnant) adults. In children, bone-Pb
may have little effect on BPb levels, but it may
help us to estimate the extent to which BPb
derives from endogenous sources and the possi-
ble contribution to the labile plasma-Pb pool.
Biomarkers for monitoring lead exposure
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